Your session is about to expire
← Back to Search
Monoclonal Antibodies
Dupilumab for Allergic Contact Dermatitis
Phase 4
Recruiting
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0, week0+72-120 hours, week 12 and week 12+72-120 hours
Awards & highlights
Study Summary
This trial will test whether the drug dupilumab can help improve symptoms in people with allergic contact dermatitis.
Eligible Conditions
- Allergic Contact Dermatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 0, week0+72-120 hours, week 12 and week 12+72-120 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0, week0+72-120 hours, week 12 and week 12+72-120 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Investigator's Global Assessment (IGA) score
Secondary outcome measures
Blood Samples
Change in Body Surface Area (BSA)
Change in Dermatology Life Quality Index (DLQI)
+4 moreSide effects data
From 2021 Phase 4 trial • 188 Patients • NCT040333679%
Conjunctivitis
7%
Headache
3%
Dermatitis Atopic
2%
Nasopharyngitis
1%
Accidental Overdose
1%
Drug Hypersensitivity
1%
Polyarthritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
DB Period: Placebo
DB Period: Dupilumab
OLE Period: Dupilumab/Dupilumab
OLE Period: Placebo/Dupilumab
Trial Design
1Treatment groups
Experimental Treatment
Group I: Subjects with Allergic Contact DermatitisExperimental Treatment1 Intervention
Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab
FDA approved
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,626 Previous Clinical Trials
11,473,592 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
635 Previous Clinical Trials
382,198 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger